Search results
29 maj 2024 · Treatment related outcomes in first-line therapy at first evaluation were 40% partial response, 20.4% stable disease, 30,9% disease progression and 1.3% complete response. G12S mutation was associated with better PFS 18.62 vs. 8.75m compared with other codon mutations (HR:0.52;95%CI 0.28-0.98) and OS NR vs. 21.58m HR (HR:0.48;95%CI;0.24-0.97).
21 cze 2024 · The US Food and Drug Administration has granted accelerated approval for the targeted therapy adagrasib (Krazati ®) in combination with the drug cetuximab (Erbitux ®) for people with advanced colorectal cancer caused by a gene mutation called KRAS-G12C.
22 sty 2024 · Background: KRAS is an oncogene that is mutated in about half of all metastatic colorectal cancers (mCRC). Recently, a novel therapy targeting KRAS G12C mutation has demonstrated promising efficacy for advanced solid tumors, including mCRC.
17 sty 2024 · Metastatic colorectal cancer patients with mutated KRAS G12C who received the KRAS inhibitor sotorasib in combination with panitumumab, a monoclonal antibody, had a longer progression-free survival compared to their counterparts who underwent standard treatment.
There is a growing unmet need for a personalized therapy approach for patients with KRAS -mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting KRAS - mutant CRC, while reviewing and elaborating on the discovery and physiology of KRAS. Keywords: colorectal cancer, KRAS mutation, targeted therapy.
Patients whose CRC harbors KRAS mutations have a dismal prognosis. Currently, KRAS mutation testing is a routine clinical practice before treating metastatic cases, and the approaches developed to detect KRAS mutations have exhibited favorable sensitivity and accuracy.
6 lis 2021 · Future directions and conclusions. KRAS is frequently mutated in CRC, and it is involved in the occurrence, progression, treatment resistance and recurrence of CRC. Considerable evidence demonstrates that KRAS mutations indicate a dismal prognosis for patients with CRC.
